Securing Expanded Patient Access: Campaign for a new medicines fund
Summary of work
EMIG’s members – small- and medium-sized pharmaceutical companies – have faced an increasingly challenging business environment in recent years as a result of the UK leaving the EU, consistently low and slow access to new medicines, and a new pricing and access scheme that required large rebates to be paid to the NHS.
Despite this, EMIG wanted to offer a positive vision for the future of UK life sciences by designing a series of business-friendly policies that could be adopted to support investment in the sector. Through targeted engagement with policymakers and officials, and by leveraging the breadth of its membership, EMIG succeeded in delivering real policy change: and the promise of expanded access to innovative medicines through the announcement of a new medicines fund.
This was such a well-executed campaign with and an excellent piece of political communication that delivered impressive outcomes. They achieved what they set out to do in a tricky political environment and did so in a very targeted and practical way.